Youxin Technology Ltd hoàn tất thâu tóm Celnet

(SeaPRwire) -   QUẢNG CHÂU, TRUNG QUỐC, ngày 30 tháng 10 năm 2025 – Youxin Technology Ltd (Nasdaq: YAAS) (“Công ty” hoặc “Youxin Technology”), nhà cung cấp phần mềm dưới dạng dịch vụ (“SaaS”) và nền tảng dưới dạng dịch vụ (“PaaS”) cam kết giúp các doanh nghiệp bán lẻ chuyển đổi kỹ thuật số hoạt động kinh doanh của mình, hôm nay đã thông báo rằng vào ngày 29 tháng 10 năm 2025, Công ty đã hoàn tất việc mua lại (sau đây gọi là “Thương vụ Mua lại”) Celnet Technology Co., Ltd. (“Celnet”), một nhà cung cấp các giải pháp tích hợp và quản lý thông tin cho doanh nghiệp và là đối tác lớn nhất của Salesforce.com tại Trung Quốc. Thương vụ Mua lại đánh dấu một cột mốc quan trọng trong việc thúc đẩy mở rộng chiến lược và quốc tế hóa của Youxin Technology và Celnet. Cùng nhau, hai công ty đặt mục tiêu cung cấp các giải pháp doanh nghiệp tiên tiến dựa trên AI, tận dụng các công nghệ mô hình lớn hiện có. Sau khi hoàn tất Thương vụ Mua lại, Youxin Technology hiện nắm giữ 51% lợi ích vốn chủ sở hữu tại Celnet. Thương vụ Mua lại dự kiến sẽ đóng góp khoảng 1,3 triệu USD doanh thu trong nửa đầu năm tài chính 2026, điều này sẽ dẫn đến mức tăng 376% doanh thu của Công ty so với cùng kỳ năm tài chính 2025. Ông Shaozhang Lin, Giám đốc điều hành của Youxin Technology Ltd, nhận xét: “Chúng tôi rất vui mừng khi hoàn tất việc mua lại Celnet, đây là một bước tiến quan trọng trong chiến lược tăng trưởng của chúng tôi. Bằng cách tích hợp các nền tảng SaaS và PaaS dựa trên đám mây của chúng tôi với chuyên môn CRM mạnh mẽ và các giải pháp hỗ trợ AI của Celnet, chúng tôi kỳ vọng sẽ tạo ra giá trị lớn hơn cho khách hàng thông qua khả năng mở rộng và mở khóa tăng trưởng doanh thu mạnh mẽ hơn. Cùng nhau, chúng tôi có vị thế tốt để tăng cường đổi mới dựa trên AI và đẩy nhanh việc thâm nhập vào các thị trường quốc tế, củng cố sức cạnh tranh và mang lại giá trị gia tăng cho các cổ đông của chúng tôi.” Về Youxin Technology Ltd Youxin Technology Ltd là nhà cung cấp SaaS và PaaS cam kết giúp các doanh nghiệp bán lẻ chuyển đổi kỹ thuật số hoạt động kinh doanh của mình bằng cách sử dụng sản phẩm SaaS dựa trên đám mây và nền tảng PaaS để phát triển, sử dụng và kiểm soát các ứng dụng kinh doanh mà không cần mua cơ sở hạ tầng CNTT phức tạp. Youxin Technology cung cấp các giải pháp kỹ thuật số đa kênh tùy chỉnh, toàn diện, triển khai nhanh chóng, hợp nhất tất cả các khía cạnh thương mại với các đổi mới cửa hàng, quản lý hàng tồn kho phân tán, tích hợp dữ liệu đa kênh và một bộ khả năng thương mại điện tử phong phú bao gồm các ứng dụng di động, mạng xã hội và ứng dụng web. Các sản phẩm của Công ty cho phép các nhà bán lẻ thương hiệu tầm trung sử dụng phân phối trực tiếp ngoại tuyến để kết nối đội ngũ quản lý, nhà phân phối, nhân viên bán hàng, cửa hàng và khách hàng cuối thông qua các hệ thống, ứng dụng và thiết bị. Điều này cung cấp cho các nhà bán lẻ một bộ công cụ toàn diện để giải quyết ngay lập tức các vấn đề bằng dữ liệu bán hàng theo thời gian thực. Để biết thêm thông tin, vui lòng truy cập trang web của Công ty: . Tuyên bố Hướng tới Tương lai Một số tuyên bố trong thông báo này là tuyên bố hướng tới tương lai. Các tuyên bố hướng tới tương lai này liên quan đến các rủi ro và sự không chắc chắn đã biết và chưa biết và dựa trên các kỳ vọng và dự báo hiện tại của Công ty về các sự kiện trong tương lai mà Công ty tin rằng có thể ảnh hưởng đến tình hình tài chính, kết quả hoạt động, chiến lược kinh doanh và nhu cầu tài chính của mình. Các nhà đầu tư có thể nhận diện các tuyên bố hướng tới tương lai này bằng các từ hoặc cụm từ như “ước tính”, “đánh giá”, “tin rằng”, “hy vọng”, “mong đợi”, “dự đoán”, “dự kiến”, “dự án”, “có ý định”, “kế hoạch”, “sẽ”, “sẽ”, “nên”, “có thể” hoặc các cách diễn đạt tương tự. Công ty không có nghĩa vụ cập nhật hoặc sửa đổi công khai bất kỳ tuyên bố hướng tới tương lai nào để phản ánh các sự kiện hoặc hoàn cảnh xảy ra sau đó, hoặc thay đổi trong kỳ vọng của mình, trừ khi luật pháp yêu cầu. Mặc dù Công ty tin rằng các kỳ vọng được thể hiện trong các tuyên bố hướng tới tương lai này là hợp lý, nhưng không thể đảm bảo rằng các kỳ vọng đó sẽ chính xác, và Công ty cảnh báo các nhà đầu tư rằng kết quả thực tế có thể khác biệt đáng kể so với kết quả dự kiến và khuyến khích các nhà đầu tư xem xét các yếu tố khác có thể ảnh hưởng đến kết quả trong tương lai của mình trong bản kê khai đăng ký của Công ty và các hồ sơ khác với SEC. Các tham chiếu và liên kết (bao gồm mã QR) đến các trang web được cung cấp để thuận tiện, và thông tin chứa trên các trang web đó không được hợp nhất bằng cách tham chiếu vào thông cáo báo chí này. Để biết thêm thông tin, vui lòng liên hệ: Youxin Technology Ltd.Bộ phận Quan hệ Nhà đầu tưEmail: Ascent Investor Relations LLCTina XiaoĐiện thoại: +1-646-932-7242Email: Bài viết được cung cấp bởi nhà cung cấp nội dung bên thứ ba. SeaPRwire (https://www.seaprwire.com/) không đưa ra bảo đảm hoặc tuyên bố liên quan đến điều đó. Lĩnh vực: Tin nổi bật, Tin tức hàng ngày SeaPRwire cung cấp phát hành thông cáo báo chí thời gian thực cho các công ty và tổ chức, tiếp cận hơn 6.500 cửa hàng truyền thông, 86.000 biên tập viên và nhà báo, và 3,5 triệu máy tính để bàn chuyên nghiệp tại 90 quốc gia. SeaPRwire hỗ trợ phân phối thông cáo báo chí bằng tiếng Anh, tiếng Hàn, tiếng Nhật, tiếng Ả Rập, tiếng Trung Giản thể, tiếng Trung Truyền thống, tiếng Việt, tiếng Thái, tiếng Indonesia, tiếng Mã Lai, tiếng Đức, tiếng Nga, tiếng Pháp, tiếng Tây Ban Nha, tiếng Bồ Đào Nha và các ngôn ngữ khác. 

Hitachi Energy and Blackstone Energy Transition Partners enter strategic partnership to create leading energy service provider in North America

Zurich and New York, October 30, 2025 - (JCN Newswire via SeaPRwire.com) - Hitachi Energy, a wholly owned subsidiary of Hitachi, Ltd., today announced a strategic partnership with Blackstone Energy Transition Partners (“Blackstone”) to expand and strengthen its Service business, supporting customers in maintaining the reliability and safety of power infrastructure across North America. As part of the partnership, Hitachi Energy will acquire a stake in Shermco – a leading provider of comprehensive maintenance, repair, testing, commissioning, and design services in North America, recently acquired by private equity funds affiliated with Blackstone.The partnership brings together three industry leaders: Hitachi Energy, a global technology leader in electrification; Blackstone, the world’s largest alternative asset manager; and Shermco, a leading provider of electrical services in the U.S. and Canada. Together, they will seek to expand service capacity and capabilities to deliver comprehensive lifecycle support for critical energy infrastructure, from power generation and transmission to data centers and industrial electrification.“Investing in Shermco in partnership with Blackstone enables Hitachi Energy to accelerate our growth and expand service capabilities across North America. Our investment strengthens our service offering as we continue to scale, helping customers maintain and extend the life of existing assets while making the grid stronger, more resilient and fit for the future.”“We’re thrilled to welcome Hitachi Energy as a strategic partner alongside Blackstone,” said Phil Petrocelli, CEO of Shermco. “This investment is a testament to our commitment to serving our customers’ essential power needs and reputation for safety and excellence. With this additional support and resources, we look forward to expanding our footprint and capabilities to continue to accelerate our growth together.”“Hitachi Energy is a global leader across technology and energy with deep digital and operational expertise,” said David Foley, Global Head of Blackstone Energy Transition Partners. “We are excited to partner with Hitachi Energy to build on Shermco's success alongside Phil Petrocelli and its exceptional management team.” JP Munfa and Darius Sepassi, Senior Managing Directors at Blackstone, added, “Hitachi Energy’s investment in Shermco brings together a global technology leader in electrification with one of the leading North American providers of mission-critical maintenance, testing and design services for electrical equipment. We are thrilled to be partnering with Hitachi Energy and look forward to working together to accelerate Shermco’s next phase of growth in an era of rapid electrification and increasing demand.”Hitachi Energy’s $1 billion global investment in ServiceIn addition, Hitachi Energy is investing more than $1 billion USD globally to expand its Service footprint, launching new digital service solutions with HMAX Energy, and growing its workforce — including the development and certification of over 5,000 additional service experts worldwide. “By combining Hitachi Energy’s grid expertise and digital solutions with Shermco’s nationwide field service presence, we will set a new benchmark for electrical infrastructure services – creating the leading service partner in North America driving asset reliability and performance as well as digital innovation for utilities, industries and data centers alike,” said Wolf Mueller, Managing Director of Hitachi Energy’s Service Business.Strengthening Service capabilities for the electricity eraGlobally, power grids are aging, and the experienced workforce is retiring, creating significant challenges. As electrification accelerates across industries, transportation, and digital infrastructure, service is the backbone of grid modernization. Much of today’s grid infrastructure – more than 70 percent of U.S. transmission lines1 – is decades old, nearing or past its intended lifecycle, leading to higher outage risks, cyber vulnerabilities and costly emergency repairs. Service is critical to help data centers, utilities and industries maintain, upgrade, and optimize their infrastructure and increase the reliability, safety, flexibility and sustainability of energy systems.1DOE, What does it take to modernize the U.S.electric grid?(1) Founded in 1974 and headquartered in Texas, Shermco is one of the largest electrical testing organizations accredited by the InterNational Electrical Testing Association (“NETA”), providing comprehensive electrical system maintenance, repair, testing, commissioning and design services, with more than 600 NETA technicians and 200 engineers across 40 service centers in the U.S. and Canada. Shermco provides critical services for data centers, utilities and diversified commercial and industrial end-markets, partnering with customers to enhance the safety, reliability and efficiency of their critical electrical infrastructure, while minimizing downtime and outages.(2) HMAX Energy is Hitachi’s upcoming digitally enabled and AI-powered services offering related to the energy sector. As a key pillar of the company’s Lumada 3.0 strategy, HMAX Energy integrates digital capabilities, domain expertise, service excellence, and installed base intelligence to maximize uptime, safety, efficiency, and asset lifetime. These capabilities will empower customers to shift from reacting to predicting - future-proofing their energy infrastructure.About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at https://www.hitachi.com.About Hitachi EnergyHitachi Energy is a global technology leader in electrification, powering a sustainable energy future with innovative power grid technologies with digital at the core. Over three billion people depend on our technologies to power their daily lives. With over a century in pioneering mission-critical technologies like high-voltage, transformers, automation, and power electronics, we are addressing the most urgent energy challenge of our time – balancing soaring electricity demand, while decarbonizing the power system. With an unparalleled installed base in over 140 countries, we co-create and build long-term partnerships across the utility, industry, transportation, data centers, and infrastructure sectors. Headquartered in Switzerland, we employ over 50,000 people in 60 countries and generate revenues of around $16 billion USD.https://www.hitachienergy.comhttps://www.linkedin.com/company/hitachienergyhttps://x.com/HitachiEnergyAbout Blackstone Energy Transition PartnersBlackstone Energy Transition Partners is Blackstone’s strategy for control-oriented equity investments in energy-related businesses, a leading energy investor with a successful long-term record, having committed over $27 billion of equity globally across a broad range of sectors within the energy industry. Our investment philosophy is based on backing exceptional management teams with flexible capital to provide solutions that help energy companies grow and improve performance, thereby delivering more reliable, affordable and cleaner energy to meet the needs of the global community. In the process, we build stronger, larger scale enterprises, create jobs and generate lasting value for our investors, employees and all stakeholders. Further information is available at https://www.blackstone.com/our-businesses/blackstone-energy-transition-partners/.About ShermcoHeadquartered in Irving, TX, Shermco provides electrical testing, maintenance, commissioning and repair services to a wide range of utility, industrial, energy and other end markets. With more than 40 locations, Shermco serves a diversified blue-chip client base across North America. The Company is an active participant in NETA (the InterNational Electrical Testing Association), EASA (Electrical Apparatus Service Association), and ACP (American Clean Power Association). For more information, visit www.shermco.com.  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Nghị viện EU có thể chặn truyền thông Nga – Politico

(SeaPRwire) -   Các trang web của RT, Sputnik và các hãng tin tức khác được cho là vẫn có thể truy cập được tại Nghị viện châu Âu bất chấp các lệnh trừng phạt Nghị viện châu Âu đang xem xét cấm các thành viên Nghị viện châu Âu (MEP) và nhân viên truy cập RT, Sputnik và các hãng tin tức Nga khác thông qua hạ tầng CNTT của mình, Politico đã đưa tin. EU đã cấm nhiều hãng truyền thông Nga như một phần của các lệnh trừng phạt áp đặt lên Moscow sau khi xung đột ở Ukraine leo thang vào tháng 2 năm 2022. Bất chấp sự kiểm duyệt, các trang web của các hãng tin Nga cũng như nhiều trang web lưu trữ nội dung của RT và Sputnik vẫn có thể được xem tại Nghị viện châu Âu, theo MEP người Latvia Rihards Kols, Politico đưa tin hôm thứ Tư. Vào giữa tháng 10, Kols, thành viên của nhóm cánh hữu European Conservatives and Reformists, được cho là đã yêu cầu các “trang web tuyên truyền của Nga đang chịu lệnh trừng phạt của EU” phải bị chặn truy cập tại cơ quan lập pháp vì lý do “an ninh thông tin.” MEP người Latvia nói với Politico rằng “đây là vấn đề an ninh thông tin, sự gắn kết thể chế và uy tín của lập trường của Nghị viện chống lại thông tin sai lệch của Nga.” Theo Kols, cơ quan quản lý truyền thông Latvia đã trực tiếp kiến nghị Chủ tịch Nghị viện châu Âu Roberta Metsola về vấn đề này. “Một giải pháp dự kiến sẽ được đề xuất trong tương lai gần,” ông nói thêm. Politico lưu ý rằng các lãnh đạo của một số nhóm chính trị tại cơ quan lập pháp đã bày tỏ lo ngại rằng các biện pháp hạn chế đối với truyền thông Nga có thể tạo tiền lệ cho việc chặn các trang web khác “vì những lý do không liên quan đến an ninh.” Họ cũng cảnh báo về những thách thức kỹ thuật và pháp lý khi thực thi các hạn chế này, bài báo cho biết thêm. Nếu được thông qua, lệnh cấm này sẽ tương tự như lệnh mà Nghị viện châu Âu đã áp đặt lên TikTok thuộc sở hữu của Trung Quốc vì lo ngại về an ninh mạng vào tháng 3 năm 2023, theo hãng tin này. Dịch vụ báo chí của cơ quan lập pháp EU đã xác nhận rằng các biện pháp hạn chế đối với truyền thông Nga sẽ được thảo luận tại các cuộc họp sắp tới của các lãnh đạo nhóm. Người phát ngôn Bộ Ngoại giao Nga Maria Zakharova trước đây cho biết rằng RT đã phải đối mặt với hơn 110 lệnh trừng phạt riêng biệt, tài khoản của hãng đã bị đóng băng, và nhân viên của hãng đã bị giám sát và quấy rối ở phương Tây. Trong lễ kỷ niệm 20 năm thành lập của hãng tin vào đầu tháng này, Tổng biên tập RT Margarita Simonyan cho biết rằng hãng vẫn tiếp tục phát sóng bất chấp chiến dịch “nực cười” ở Mỹ và EU nhằm mục đích ngừng phát sóng kênh và chặn các tài khoản trực tuyến của hãng. Simonyan gọi các lệnh trừng phạt là “những bất tiện nhỏ,” nói rằng RT “chỉ ngày càng mạnh hơn và cảm thấy tự tin hơn” nhờ đó.Bài viết được cung cấp bởi nhà cung cấp nội dung bên thứ ba. SeaPRwire (https://www.seaprwire.com/) không đưa ra bảo đảm hoặc tuyên bố liên quan đến điều đó. Lĩnh vực: Tin nổi bật, Tin tức hàng ngày SeaPRwire cung cấp phát hành thông cáo báo chí thời gian thực cho các công ty và tổ chức, tiếp cận hơn 6.500 cửa hàng truyền thông, 86.000 biên tập viên và nhà báo, và 3,5 triệu máy tính để bàn chuyên nghiệp tại 90 quốc gia. SeaPRwire hỗ trợ phân phối thông cáo báo chí bằng tiếng Anh, tiếng Hàn, tiếng Nhật, tiếng Ả Rập, tiếng Trung Giản thể, tiếng Trung Truyền thống, tiếng Việt, tiếng Thái, tiếng Indonesia, tiếng Mã Lai, tiếng Đức, tiếng Nga, tiếng Pháp, tiếng Tây Ban Nha, tiếng Bồ Đào Nha và các ngôn ngữ khác. 

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

SHENZHEN, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world's first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC).MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10.The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China.If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon's ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon's product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector.On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.About AD IndicationMG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group.Reference:1. China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry2. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Quantum Solutions Trở Thành Nhà Nắm Giữ ETH Tổ Chức Lớn Nhất Châu Á Với Sự Hậu Thuẫn Từ Cathie Wood Của ARK Invest

(SeaPRwire) -   Tokyo, Nhật Bản, ngày 30 tháng 10 năm 2025 -- Quantum Solutions Co., Ltd. (TSE: 2338), công ty niêm yết trên Tokyo Stock Exchange, đã chính thức trở thành tổ chức nắm giữ Ethereum (ETH) lớn nhất châu Á, đánh dấu một cột mốc quan trọng trong việc các công ty đại chúng trong khu vực chấp nhận tài sản kỹ thuật số. Thông báo này được đưa ra sau khi công ty tích lũy được 2.365 ETH chỉ trong bảy ngày, và đã nhận được sự tán thành công khai từ CEO ARK Invest Cathie Wood, báo hiệu niềm tin quốc tế ngày càng tăng vào chiến lược kho bạc tài sản kỹ thuật số (DAT) của Quantum Solutions và vai trò dẫn đầu của công ty trong quá trình chuyển đổi của Nhật Bản hướng tới cơ sở hạ tầng tài chính dựa trên blockchain.Cathie Wood bình luận:“Ba tháng kể từ cuộc cách mạng DAT, chúng tôi rất vui được hỗ trợ DAT ETH cấp tổ chức đầu tiên của Nhật Bản.Mở rộng khả năng tiếp cận đổi mới trong thị trường vốn toàn cầu là rất quan trọng — chúng tôi rất vui khi thực hiện điều này cùng với @Quantum_SKK2338 và @FrancisBZhou.”Bài đăng trên X của Cathie Wood: Francis B. Zhou, CEO của Quantum Solutions, cho biết thêm:“Chúng tôi đã tích lũy được 2.365 ETH chỉ trong bảy ngày, chính thức đưa Quantum Solutions trở thành DAT ETH lớn nhất bên ngoài Hoa Kỳ. Sẽ có thêm ETH.”Mở rộng dự trữ tài sản kỹ thuật số trên khắp châu ÁTheo Quantum Solutions, công ty — thông qua công ty con tại Hồng Kông là GPT Pals Studio Limited — đã và đang liên tục mở rộng dự trữ tài sản kỹ thuật số của mình.Lượng nắm giữ ETH của công ty hiện đứng đầu trong số tất cả các công ty niêm yết ở châu Á, đánh dấu một cột mốc quan trọng khác trong chiến lược dài hạn nhằm xây dựng một mô hình lai tích hợp AI, Web3 và quản lý kho bạc tài sản kỹ thuật số.Một kỷ nguyên mới cho thị trường vốn Nhật BảnThông báo này báo hiệu sự chuyển động nhanh chóng của Nhật Bản hướng tới kỷ nguyên blockchain cấp tổ chức và định vị Quantum Solutions là một công ty kho bạc tiền điện tử tiên phong niêm yết công khai, tiếp bước MetaPlanet.Sự tán thành của Cathie Wood phản ánh niềm tin quốc tế mạnh mẽ vào tầm nhìn chiến lược, tiêu chuẩn quản trị và tính minh bạch của Quantum Solutions.Các nhà phân tích trong ngành lưu ý rằng sáng kiến này không chỉ đa dạng hóa bảng cân đối kế toán của công ty mà còn nâng cao sự hiện diện của Nhật Bản trong hệ sinh thái tài chính kỹ thuật số toàn cầu.Tổng quan về công tyQuantum Solutions Co., Ltd. (Mã Tokyo Stock Exchange: 2338) là một công ty công nghệ Nhật Bản niêm yết công khai chuyên về quản lý Kho bạc Tài sản Kỹ thuật số (DAT).Được định hướng bởi triết lý “Công nghệ dựa trên tài sản”, công ty đang xây dựng một hệ sinh thái đổi mới tích hợp các công nghệ AI, Web3 và nội dung trò chơi.Quantum Solutions cam kết thiết lập một nền tảng tạo giá trị bền vững kết nối thị trường vốn với công nghệ tiên tiến, đồng thời mở rộng dấu ấn kinh doanh từ Nhật Bản sang châu Á và thị trường toàn cầu.Mọi thắc mắc truyền thông xin liên hệ:Quantum Solutions Co., Ltd.Bộ phận Kế hoạch Doanh nghiệp – Đại diện IR: Catherine TeradaE-mail: ir@quantum-solutions.co.jpTrang web: Tuyên bố miễn trừ trách nhiệm: Thông tin được cung cấp trong thông cáo báo chí này không phải là lời mời gọi đầu tư, cũng không nhằm mục đích tư vấn đầu tư, tư vấn tài chính hoặc tư vấn giao dịch. Đầu tư luôn tiềm ẩn rủi ro, bao gồm khả năng mất vốn. Bạn nên thực hiện thẩm định kỹ lưỡng, bao gồm tham khảo ý kiến của cố vấn tài chính chuyên nghiệp, trước khi đầu tư hoặc giao dịch tiền điện tử và chứng khoán. Cả nền tảng truyền thông lẫn nhà xuất bản đều không chịu trách nhiệm về bất kỳ hoạt động gian lận, xuyên tạc hoặc tổn thất tài chính nào phát sinh từ nội dung của thông cáo báo chí này.  Bài viết được cung cấp bởi nhà cung cấp nội dung bên thứ ba. SeaPRwire (https://www.seaprwire.com/) không đưa ra bảo đảm hoặc tuyên bố liên quan đến điều đó. Lĩnh vực: Tin nổi bật, Tin tức hàng ngày SeaPRwire cung cấp phát hành thông cáo báo chí thời gian thực cho các công ty và tổ chức, tiếp cận hơn 6.500 cửa hàng truyền thông, 86.000 biên tập viên và nhà báo, và 3,5 triệu máy tính để bàn chuyên nghiệp tại 90 quốc gia. SeaPRwire hỗ trợ phân phối thông cáo báo chí bằng tiếng Anh, tiếng Hàn, tiếng Nhật, tiếng Ả Rập, tiếng Trung Giản thể, tiếng Trung Truyền thống, tiếng Việt, tiếng Thái, tiếng Indonesia, tiếng Mã Lai, tiếng Đức, tiếng Nga, tiếng Pháp, tiếng Tây Ban Nha, tiếng Bồ Đào Nha và các ngôn ngữ khác.  LIÊN HỆ: Catherine Terada Quantum Solutions Co., Ltd ir (at) quantum-solutions.co.jp

Zhihu Inc. sẽ công bố kết quả kinh doanh quý 3 năm 2025 vào ngày 25 tháng 11 năm 2025

(SeaPRwire) -   BẮC KINH, Trung Quốc, ngày 30 tháng 10 năm 2025 -- Zhihu Inc. (“Zhihu” hoặc “Công ty”) (NYSE: ZH; HKEX: 2390), một cộng đồng nội dung trực tuyến hàng đầu tại Trung Quốc, hôm nay đã thông báo rằng họ sẽ công bố kết quả tài chính chưa kiểm toán cho quý kết thúc vào ngày 30 tháng 9 năm 2025 trước khi thị trường Hoa Kỳ mở cửa vào ngày 25 tháng 11 năm 2025. Ban lãnh đạo Công ty sẽ tổ chức một cuộc gọi hội nghị vào lúc 6:00 sáng Giờ miền Đông Hoa Kỳ vào Thứ Ba, ngày 25 tháng 11 năm 2025 (7:00 tối Giờ Bắc Kinh/Hồng Kông vào Thứ Ba, ngày 25 tháng 11 năm 2025) để thảo luận về kết quả. Tất cả những người tham gia muốn tham gia cuộc gọi hội nghị phải đăng ký trước trực tuyến bằng cách sử dụng liên kết được cung cấp dưới đây. Sau khi hoàn tất đăng ký trước, mỗi người tham gia sẽ nhận được một bộ số quay số và một mã PIN truy cập duy nhất có thể được sử dụng để tham gia cuộc gọi hội nghị. Liên kết đăng ký: Ngoài ra, một buổi truyền hình trực tuyến (webcast) trực tiếp và lưu trữ của cuộc gọi hội nghị sẽ có sẵn trên trang web quan hệ nhà đầu tư của Công ty tại . Về Zhihu Inc. Zhihu Inc. (NYSE: ZH; HKEX: 2390) là một cộng đồng nội dung trực tuyến hàng đầu nơi mọi người đến để tìm giải pháp, đưa ra quyết định, tìm kiếm cảm hứng và giải trí. Kể từ khi ra mắt ban đầu vào năm 2010, Zhihu đã phát triển thành cộng đồng nội dung trực tuyến lớn nhất theo định hướng hỏi đáp (Q&A) tại Trung Quốc. Để biết thêm thông tin, vui lòng truy cập . Đối với các câu hỏi của nhà đầu tư và truyền thông, vui lòng liên hệ: Zhihu Inc.Email: Christensen AdvisoryRoger HuĐiện thoại: +86-10-5900-1548 Email: Bài viết được cung cấp bởi nhà cung cấp nội dung bên thứ ba. SeaPRwire (https://www.seaprwire.com/) không đưa ra bảo đảm hoặc tuyên bố liên quan đến điều đó. Lĩnh vực: Tin nổi bật, Tin tức hàng ngày SeaPRwire cung cấp phát hành thông cáo báo chí thời gian thực cho các công ty và tổ chức, tiếp cận hơn 6.500 cửa hàng truyền thông, 86.000 biên tập viên và nhà báo, và 3,5 triệu máy tính để bàn chuyên nghiệp tại 90 quốc gia. SeaPRwire hỗ trợ phân phối thông cáo báo chí bằng tiếng Anh, tiếng Hàn, tiếng Nhật, tiếng Ả Rập, tiếng Trung Giản thể, tiếng Trung Truyền thống, tiếng Việt, tiếng Thái, tiếng Indonesia, tiếng Mã Lai, tiếng Đức, tiếng Nga, tiếng Pháp, tiếng Tây Ban Nha, tiếng Bồ Đào Nha và các ngôn ngữ khác. 

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

SHENZHEN, CHINA – October 30, 2025 – (SeaPRwire) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC). MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China. If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon’s ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon’s product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector. On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China. About AD Indication MG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/

Esperanza Unveils New Milestone in Tokenized Economy

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Esperanza Fintech (Hong Kong) Limited (“Esperanza” or the “Group”) today hosted the “Conference: Implementation of Tokenized Economy by Esperanza” (“Conference”). It is an opportune moment as the Hong Kong SAR Government vows in her 2025 Policy Address to support the development of tokenized gold investment products. The Conference brought together industry leaders and partners to map out a strategic blueprint to implement tokenized economy, including the compliant roadmap for tokenized gold in Hong Kong and the unlimited potential of tokenized investments, an application for tokenized gold, in driving economic growth in the Asia-Pacific region. The Conference was attended by nearly a hundred investors and professionals.The Conference kicked off with a vision speech delivered by Mr. Ronald Leung, solicitor, Founder and Group CEO of Esperanza. Mr. Leung pointed out that the Asia-Pacific region has long relied on Western settlement systems and Western-dominated interest rate policies. The tokenized economy, powered by tokenized gold, offers an alternative capital solution to drive regional economic development and the continuous internationalization of the financial and capital markets of the Chinese Mainland  and Hong Kong . He emphasized that the support for development of tokenized gold in Hong Kong’s 2025 Policy Address is a highly strategic policy direction. Capitalizing on her status and resources as an international financial center, Hong Kong possesses unparalleled edge in developing an ecosystem powered by tokenized gold in facilitating cross-border trades in the Asia-Pacific region. Furthermore, tokenized gold could be integrated with Central Bank-led digital Renminbi (RMB) in the future to contribute to the internationalization of RMB. He pointed out that the Group has completed registration with the Hong Kong Customs as an issuer of precious asset-backed instrument. The Group has also undergone a small-scale, non-public proof-of-concept (POC) testing in multiple Asia Pacific markets, including Southeast Asia, Australia, Japan, South Korea, and currently has significant verified “Know Your Customer (KYC)” POC users. Although Esperanza's tokenized gold is designed based on the legal framework for precious asset-backed instrument registered with Hong Kong Customs, to ensure overall regulatory stability in Hong Kong, it is anticipated that Esperanza will open its tokenized gold offerings to the Hong Kong public only after addressing the concerns of other regulatory bodies and when a clear regulatory framework is fully implemented in the city. The Group will also align with governments of various economies on operational fronts via strategic partners.Mr. Leung continued to point out, "Tokenized gold is a key milestone for Hong Kong's financial future. Esperanza has already signed an agreement with Hatcher Group Limited (8365.HK) regarding the development of tokenized gold before the Policy Address was released. Immediately following the release, our team has conducted a productive and in-depth communication with the Chief Executive's Policy Unit, while ensuring our technology platform and infrastructure are in place and ready for action. Currently, we are maintaining active dialogues with regulators, with the core principle of achieving ‘controllable innovation’ that adheres to existing regulatory framework as well as the work agenda of the Chief Executive’s Policy Unit. We firmly believe that Esperanza, armed with first-mover advantages in technology and its business model, and in collaboration with various sectors, will be able to transform tokenized gold into a powerful engine in driving economic autonomy in the Asia-Pacific region."The conference had two thematic sharing sessions. The first had Mr. Roy Lui, Managing Director of ESPE Gold Solutions, sharing the compliant implementation of tokenized gold in Hong Kong. Mr. Lui shared that the Group’s proposed solution – “ESPE Gold” (“ESPG”) – is legally categorized as a “precious asset-backed instrument” instead of a virtual asset or a stablecoin, nor a collective investment scheme. Esperanza purchases physical gold bars adhering to London Bullion Market Association (LBMA) standards, stores them in licensed gold vaults and issues 100,000 ESPG, i.e. digital gold certificates, for each kilogram of gold bar. These digital gold certificates, each representing a complete instalment payment, are recorded on blockchain networks. Upon completion of 100,000 instalments, i.e. holding 100,000 ESPG, clients can redeem physical gold bars from Esperanza. Clients can make instalment payments any time and sell ESPG back to Esperanza, enjoying much higher flexibility than traditional gold redemption clubs. Mr. Lui emphasized that, although ESPG gives users experiences similar to that of stablecoins, the business model is actually more akin to traditional gold dealers earning bid-ask spread. He also spoke on the diverse application scenarios of ESPG besides as a convenient way to purchase physical gold. ESPG is poised to develop into a cross-border settlement means for commerce across Asia economies, with future potential to power a gold-backed interest rate system through collateralized lending of ESPG.In the second sharing session, Mr. Tony Chang, Executive Director of ESPE Capital Solutions, talked about the Group’s blueprint for tokenized investments as a core use case for tokenized gold. Mr. Chang said tokenized investments have not seen significant breakthrough due to the lack of product designs that are attractive to investors and that liquidity is highly concentrated within professional investors. Tokenized investments need to deliver both “attractive growth potential” and “security in exit channels” in order for investors to make meaningful consideration for adoption. Such example includes a short-term revenue sharing arrangement with foreseeable potential for revenue improvement. He added that Esperanza has obtained the Asset Management licence from the Securities and Futures Commission (SFC) of Hong Kong and its application for tokenized business is currently under review, with the legal, tax, and trading infrastructures ready. Currently, the Group’s tokenized investment pipelines include concert revenue of Southeast Asian and Korean artists, movie box office receipts and revenue of hotels and shopping malls.In addition to the thematic sharing sessions, the conference also featured a panel discussion comprising Mr. Jeremy Teo from Singapore, Co-founder and Board Director of Esperanza, Mr. Ronald Leung and Mr. Tony Chang. The discussion centers on the development potential of tokenized gold and tokenized investments across various Asia-Pacific economies, particularly the opportunities in bringing Southeast Asian projects to Hong Kong for capital raising via security token offerings (STOs). These opportunities illustrate the advantages for Hong Kong in developing tokenized gold with the support of the Hong Kong SAR Government.The conference marked an important step made by Esperanza in promoting the development of tokenized economy in Hong Kong and across Asia. Looking ahead, the Group will continue to provide innovative fintech solutions to support Hong Kong in strengthening her position as an international financial center, as well as helping foster greater economic autonomy and financial innovation in the Asia-Pacific region.Photo captionsPhoto 1: (From left to right) Mr. Tony Chang, Executive Director of ESPE Capital Solutions, and Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Roy Lui, Managing Director of ESPE Gold Solutions, at the conference.Photo 2: (From left to right) Mr. Jeremy Teo, Co-founder and Board Director of Esperanza, Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Tony Chang, Executive Director of ESPE Capital Solutions, after the panel discussion session.About Esperanza Fintech (Hong Kong) Limited (Esperanza)Esperanza is co-founded by the next generation of professionals from Hong Kong and Singapore with the mission to reform Asia’s economies through fintech. Esperanza is building the world’s first digital economy powered by a compliant tokenized gold infrastructure and its applications in finance. Esperanza aspires to reconnect Asia’s economies and integrate with their respective Central Bank Digital Currencies (CBDCs) to build autonomy against reliance on Western settlement systems and interest rate policies.Esperanza operates on a low-profile, highly efficient, and decisive business model. Since commencement in 2025, Esperanza has secured the registration as a Precious Metals and Stones Dealer (DPMS) with Hong Kong Customers and the Trust or Company Service Provider (TCSP) licence for the operations and custody of tokenized gold, and the Asset Management licence with the Securities and Futures Commission (SFC) of Hong Kong for the development of tokenized investments.In August 2025, Esperanza entered into a partnership agreement with Hatcher Group (8365.HK) relating to tokenized gold and tokenized investments. In September 2025, Hong Kong government has included the development of tokenized gold into its 2025 Policy Address.Esperanza's tokenized gold and tokenized investments continue to adhere to Hong Kong's Anti-Money Laundering (AML) requirements and common reporting standard for counter-tax evasion measures. Fintech solutions have enabled Esperanza to significantly reduce financing and operational costs, connecting products directly with end users. Esperanza’s tokenized finance system will fully support the globalization of national economy and is committed to becoming an alternative solution for international trades and settlements.To find out more, please visit the Esperanza website: espetopia.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MHI-MS to Conduct Demonstration Testing of Vehicle Transport Robots at Nakagusuku Port in Okinawa

Vehicle transport robotsTOKYO, October 30, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Machinery Systems (MHI-MS), a part of Mitsubishi Heavy Industries (MHI) Group, will conduct demonstration testing of finished vehicle logistics (FVL) using vehicle transport robots to autonomously move automobiles. Following a proposal adopted for "Testbed Support Subsidy Program"(*1) conducted by Okinawa Prefecture, demonstration testing is scheduled to begin on December 1 this year at the prefecture's temporary vehicle storage yard (motor pool) at Nakagusuku Port (Uruma, Okinawa Prefecture).Vehicle transport robots are used to autonomously move finished vehicles at automobile manufacturing plants, motor pools, and for automated valet parking at shopping malls, theme parks, and airports.(*2) The system enables automated transport even if the vehicle itself is not equipped with autonomous driving capabilities or communication functions, and can be widely utilized in motor pools for both new and used cars without the need for vehicle modification or extensive installation of equipment on the infrastructure side, and without major changes to current operations.MHI-MS has been jointly developing the first advanced automated transport robot business in Japan with Stanley Robotics, a French venture company, since 2021. As of October 2025, seven core patents have been registered in Japan for automated transport robots, which will drive market expansion. In consideration of the unique conditions in Japan, domestic development of a customizable system was completed in March this year.Okinawa, the site of the demonstration testing for finished vehicle transport, is a region with a high rate of private car ownership, with the number of private cars owned per capita of the population over the age of 20 exceeding the national average. Used cars especially are preferred by many prefectural residents because they are less expensive than new cars, and play an important role in the infrastructure supporting everyday life. In addition, because of the many tourist arrivals in Okinawa from Japan and abroad, the number of rental car registrations is one of the highest in Japan. Registered rental cars are replaced every few years and sold on the market as used cars. In this way, the used car market supports Okinawa's industry and the everyday lives of people.The Nakagusuku Port Motor Pool is mainly used for temporary storage of used cars prior to shipping, and transport services such as the loading and unloading of used cars are conducted at the site on a regular basis. In addition, the outdoor work environment has become harsher due to global warming, so reducing the physical burden on workers and ensuring a sustainable working style is an urgent matter. Strategies to address labor shortages due to the declining birth rate and aging population have also become a concern. In addition, the application of DX (digital transformation) technologies for vehicle management, such as visualization of the storage location of used cars, was also a factor for future consideration.MHI-MS decided to participate in this program in Okinawa Prefecture to demonstrate the effectiveness of vehicle transport robots as a solution to such challenges. The demonstration testing will evaluate the potential for improving the working environment, and responding to labor shortages, as well as "human-centered robot utilization" such as robot-based yard management systems and DX to handle vehicle location information. The tests will also evaluate the potential contribution to decarbonization efforts by confirming supplemental benefits such as curbing CO2 emissions through reduced driving of gasoline-powered vehicles.Going forward, as a company committed to creating new value for society and solving future societal issues through mechatronics, MHI-MS will establish a new future for finished vehicle transport that is friendly to both people and the planet.(*1) "Testbed Support Subsidy Program (Okinawa Prefecture Subsidy Program)" provides support for proof-of-concept experiments within Okinawa Prefecture by companies with innovative digital technologies and services, with the aim of furthering innovation and solutions to societal issues. See the following website for more information about the program. https://testbedislandokinawa.com (Japanese)(*2) When the driver stops at a designated berth close to the facility, the vehicle transport robot moves the vehicle to a vacant space, taking over parking on behalf of the driver. The process is reversed when retrieving the vehicle, with the robot transporting the vehicle back to the berth at the time specified by the driver in advance using the smartphone app. For drivers, there is no need to find a parking space or park, and no concerns about brushing against the adjacent car when opening the door.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol “NBP”), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries.This collaboration marks Everest’s strategic expansion into ophthalmology, a high-potential “blue-ocean” therapeutic area, further enriching its late-stage product pipeline and strengthening synergies across its core therapeutic portfolio.Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales.“We are pleased to collaborate with Visara. This partnership brings a highly differentiated and commercially attractive asset to Everest’s late-stage product pipeline and marks our entry into ophthalmology, a competitively attractive therapeutic area with significant unmet medical needs,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Leveraging Everest’s clinical development and commercialization expertise, we look forward to advancing VIS-101, a potential best-in-class bifunctional antibody, towards commercialization in China and across Asia.”VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2 that is more potent and could potentially provide more durable treatment benefits than existing treatments for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed initial safety and dose-escalation studies in both the United State of America and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.“VIS-101 is anticipated to be second-in-class with best-in-class potential, based on bioengineered, superior target neutralizing capabilities.” said Dr. Emmett T. Cunningham, Jr, Co-Founder and Executive Chairman of Visara.Globally, the market size for anti-VEGF ophthalmic drugs reached approximately USD 23 billion in 2024 and is projected to exceed USD 40 billion by 2030. In China alone, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment. This indicates vast market potential.Visara is a subsidiary of NovaBridge Biosciences (Nasdaq: NBP), of which Everest Medicines is currently the largest shareholder. “Licensing out Greater China, South Korea and Southeast Asia rights to Everest Medicines is an important step toward streamlining global commercial rights and creating synergy in global clinical development,” said Dr. Sean Fu, Chief Executive Officer of NovaBridge Biosciences. “We are excited to work with Everest Medicines team as a strategic partner."Under its “dual-engine” strategy, Everest Medicines has established a commercialization platform anchored by two blockbuster products targeting high-potential markets and powered by the in-house in vivo CAR-T and mRNA therapeutic cancer vaccine platforms. The Company will continue to focus on key therapeutic areas and new growth markets, with ophthalmology as the next growth driver to strengthen synergy across its core portfolio.Everest’s core product pipeline in rental diseases, infectious diseases, and autoimmune disorders has entered a critical growth stage. NEFECON® and XERAVA® have established sustainable commercial cash flow generation, while VELSIPITY® (etrasimod) is expected to become the company’s next blockbuster product. Everest continues to enhance its innovation capability and long-term competitiveness by leveraging its industry-leading mRNA therapeutic cancer vaccine platform and mRNA in vivo CAR-T platform.At a recent corporate strategy meeting, Everest Medicines announced plans to in-license more than three high-potential assets within the next 6–12 months, with an aggregate domestic peak sales potential exceeding RMB10 billion. Combined with its existing portfolio, Everest Medicines expects its total domestic peak sales potential to surpass RMB20 billion. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

DENSO Hosted a Press Briefing at JAPAN MOBILITY SHOW 2025

KARIYA, JAPAN, Oct. 30, 2025 - (JCN Newswire via SeaPRwire.com) - DENSO CORPORATION hosted a press briefing at JAPAN MOBILITY SHOW 2025 held at Tokyo Big Sight on October 30.  Shinnosuke Hayashi, President & CEO, DENSO CORPORATIONFull transcript of the speech------------------------------Good morning, I’m Shinnosuke Hayashi from DENSO.Thank you very much for joining us today.Since its founding, DENSO’s journey has evolved alongside the automobile. By focusing on the environment and safety, we have addressed social challenges and expanded our product domains from starter and alternator systems to powertrain, body, thermal, and safety products—covering a wide range of core vehicle functions.To ensure vehicle performance and reliability, we have also pursued deep technological expertise in each domain, evolving our offerings from components to systems.This breadth and depth of technology are unique strengths of DENSO, supporting both the evolution of automobiles and the future of mobility.Today, the world is steadily moving toward carbon neutrality. In the automotive industry, reducing environmental impact and responding to increasingly diverse powertrains have become key challenges.Leveraging our fuel efficiency and emission reduction technologies, along with our electrification expertise, DENSO continues to tackle these challenges by offering products for engine vehicles, HEVs, PHEVs, battery EVs, and FCEVs.Now, we are pleased to announce the development of a new inverter—the core component of electric vehicles.The key to inverter performance lies in semiconductor and cooling technologies.Through extensive R&D—from circuit design to manufacturing processes—we’ve realized a proprietary 3D structure on SiC(silicon carbide) semiconductor wafers, maximizing power efficiency. Additionally, by applying cooling technologies cultivated through car air conditioning systems, we’ve achieved a flat, double-sided cooling structure for the power card. By optimally integrating these technologies as a system, we have reduced power loss by 70% and downsized the core module by about 30% compared to conventional products.This results in the world’s highest power density, contributing to improved energy efficiency across the vehicle.Meanwhile, in the era of Software-Defined Vehicles (SDVs), vehicle intelligence is accelerating through advanced driver assistance and autonomous driving. System-on-Chip (SoC) semiconductors are gaining attention as high-performance digital components capable of running sophisticated software.Unlike general-purpose SoCs, automotive SoCs must withstand harsh conditions unique to vehicles.For over half a century, DENSO has tackled technical challenges such as heat, noise, and vibration in semiconductor development.Building on this experience, we are developing original SoCs that deliver high performance and reliability tailored to automotive needs.We are also advancing the development of an “Integrated Mobility Computer” that controls multiple domains across the vehicle, leveraging our expertise in ECU development across all areas.This computer will help accelerate the spread of vehicle intelligence, contributing to safer and more comfortable mobility for more users.We aim to launch the Integrated Mobility Computer equipped with our original SoC in 2029.Production is planned at our next-generation factory in Aichi Prefecture (Zenmyo Plant), which will use advanced technologies to operate 24 hours a day.DENSO will extend its efforts toward the environment and safety beyond the evolution of automobiles to encompass the entire mobility society.At this year’s Japan Mobility Show, we are showcasing initiatives that expand these efforts to society —such as energy management across entire cities and safe, comfortable mobility realized through vehicles connected to society.We invite you to visit our exhibits and experience the future of mobility with DENSO.“With refined technology, we open the future.”We have taken on numerous challenges through the power of technology.The driving force behind this is the passion of the people involved in manufacturing.DENSO will continue to unite the passion of our employees, and together with automakers and many partners who share our vision for the future, we will keep taking on new challenges.Thank you very much for your attention.-------------------------Videos and images from the press conference are also available at the link below. https://www.denso.com/global/en/about-us/corporate-info/press-info  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Gannon & Scott has signed a definitive agreement to join Metalor Technologies

Cranston, RI, USA & Neuchâtel, Switzerland, Oct 29, 2025 - (JCN Newswire via SeaPRwire.com) - Gannon & Scott, a leading provider of precious metal refining and recovery services in North America, today announced that it has signed a definitive agreement to join Metalor Technologies, one of the most respected names in the global precious metals industry and part of TANAKA. The transaction is expected to close following approval by regulatory authorities, after which Gannon & Scott will become a wholly owned subsidiary of Metalor Technologies, enhancing the capabilities of both organizations and positioning them to better serve their worldwide customer base.Founded in 1919, Gannon & Scott has earned a strong reputation for secure, environmentally responsible refining solutions across industries including electronics, aerospace, electroplating, medical devices, and jewelry manufacturing. With facilities in Rhode Island and Arizona, the company is recognized for its proprietary thermal reduction technology and waste minimization processes — innovations that align seamlessly with Metalor Technologies’ global standards for excellence.“We are thrilled to become part of an organization that shares our commitment to innovation, customer success, and sustainable growth,” said Christopher Jones, President of Gannon & Scott. “This partnership allows us to build on our strengths while gaining new resources and opportunities. Together, we are well positioned to deliver even greater results for our customers, employees, and partners.”A Stronger Offering for CustomersAs part of Metalor Technologies, Gannon & Scott customers will benefit from:Expanded refining capabilities across all precious metals (gold, silver, platinum, palladium, rhodium, iridium, ruthenium) through global sourcing and recycling channels.Access to high-purity precious metals, technical products, compounds, and chemicals. Advanced technology and analytical services powered by Metalor Technologies’ international laboratories and R&D network.A global refining infrastructure enabling more agile service to international operations.“Since 1919, Gannon & Scott has consistently grown. Becoming part of Metalor Technologies provides a tremendous opportunity to accelerate that growth,” said Joe Peixoto, CEO of Gannon & Scott. “It opens the door to new capabilities, new markets, and new professional development opportunities for our employees. Our customers can be assured that the high level of service, trust, and security they’ve always relied on will remain unchanged — now strengthened by access to a broader suite of products and services.”Customers can expect a seamless transition. In particular, Gannon & Scott’s leadership team, skilled workforce, facilities, and day-to-day operations will remain unchanged.“The acquisition of Gannon & Scott, the most reputable secondary refiner in the United States, represents a strategic step in strengthening Metalor Technologies’ vertical integration,” said Nicolas Carrera, CEO of Metalor Technologies. “By securing direct access to low-grade materials such as electronic waste, we reinforce our commitment to sustainable sourcing and responsible recycling of precious metals, while expanding our ability to serve customers and partners with greater efficiency and environmental responsibility.”“Joining the forces of Gannon & Scott with our existing refining operations in the United States, which have recently begun refining PGMs, will significantly enhance our ability to serve the American market,” said Dr. Yuxing Shang, President of Metalor Technologies’ Refining Group. “This integration allows us to expand the range of services we can offer to both current and future customers in North America, combining advanced capabilities with the trusted expertise of Gannon & Scott.”“We warmly welcome the collaboration between Gannon & Scott and Metalor,” said Koichiro (Frank) Tanaka, Group CEO of TANAKA. “Their partnership will create new synergies within TANAKA, further strengthening our shared commitment to sustainable and responsible precious metal refining for customers and industries worldwide.”About Gannon & Scott Gannon & Scott provides precious metal refining, thermal processing, and secure materials recovery services to businesses across North America. With operations in Cranston, RI, and Phoenix, AZ, the company serves sectors including electronics, plating, jewelry, aerospace, and certified destruction.About Metalor TechnologiesFounded in 1852, Metalor is a global leader in precious metals refining, advanced materials, and fine chemicals. Headquartered in Switzerland with operations in Europe, Asia, and the Americas, and more than 1,550 employees worldwide, Metalor is recognized for its refining excellence, high-quality products, and long-standing partnerships across banking, luxury goods, electronics, and chemical sectors. The company is part of TANAKA.About TANAKAFounded in 1885 and headquartered in Japan, TANAKA offers a broad range of advanced precious metal materials for industrial use, as well as assets and jewelry. As a global precious metals specialist, TANAKA’s group companies worldwide collaborate in procurement, R&D, manufacturing, sales, customer service, and recycling to deliver comprehensive products and services. The group has 5,591 employees, and its consolidated net sales for fiscal year 2024 totaled 846.9 billion yen (approximately 5.96 billion USD).Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.co.jp/support/req/other_contact_e/index.htmlPress release: http://www.acnnewswire.com/docs/files/251028.pdf  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center

TOKYO, Oct 29, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of the NBI+TXI™ observation mode, which combines Narrow Band Imaging (NBI™ mode) and Texture and Color Enhancement Imaging (TXI™ mode) into a single view. Sales of the EVIS X1™ endoscopy system featuring the NBI+TXI mode will begin in Japan in November 2025, with launches in other regions to follow pending local regulatory approvals.The latest NBI mode, and the TXI observation mode, combined in the CV-1500.Since its initial launch in April 2020, the EVIS X1 endoscopy system has supported healthcare professionals with advanced imaging technologies including TXI mode, NBI mode and RDI™ mode (Red Dichromatic Imaging). These proprietary innovations have contributed to more precise observation and treatment of gastrointestinal and respiratory diseases, including cancer.The NBI+TXI mode further strengthens the EVIS X1 endoscopy system’s diagnostic capabilities by enhancing the brightness correction and contrast information of NBI mode. This enables clearer visualization in darker areas of the image and sharper definition of vascular and mucosal patterns, which can contribute to improved detection and diagnostic accuracy for lesions, including those associated with cancers.According to 2021 statistics from the Ministry of Health, Labour and Welfare1, colorectal cancer has the highest incidence rate among all types of cancer in Japan, with 154,585 cases, followed by lung cancer (124,531 cases), and stomach cancer (112,881 cases). These cancers also rank among the leading causes of cancer-related deaths, with lung cancer first (75,762 deaths), colorectal cancer second (53,131 deaths), and stomach cancer fourth (38,771 deaths).NBI mode, first introduced globally in 2006, brought a revolutionary change to endoscopic imaging by improving visibility of features that were previously difficult to detect, making the invisible visible. The CV-1500 incorporates the latest NBI mode, achieving improved brightness compared to the original NBI mode. TXI mode, introduced with the CV-1500, further improves the visibility of lesions through its image enhancement technology when used with conventional light observation. The combination of these two technologies in the CV-1500, the NBI+TXI observation mode is expected to further enhance and optimize the contrast information in NBI mode images, supporting more precise endoscopic examinations and treatments.NBI+TXI observation mode is expected to enhance the contrast information in NBI mode imaging.Supporting Better Mucosal VisibilityTXI mode supports better visibility of potential and extant lesions, such as areas of inflammation, flat or depressed lesions, or even tiny precursor lesions, by enhancing texture, brightness and color to define subtle tissue differences more clearly. With its advanced imaging technology, TXI mode has the potential to reinvent white light in endoscopy. By supporting better visibility of potential and extant lesions, TXI mode may contribute to higher detection rates and improve qualitative diagnosis.NBI mode is a powerful and proven optical technology creating strong contrast between vessels and surrounding mucosa that allows for a high-confidence optical diagnosis using specific blue and green wavelengths. NBI mode not only supports earlier detection of lesions but also provides a more detailed, higher-contrasted visualization that can improve qualitative diagnosis.“We know that early detection improves patient care and outcomes.” said Kurt Heine, Senior Vice President and General Manager for Gastroenterology, Olympus. “Olympus is committed to providing the advanced endoscopic imaging physicians need to clearly visualize the GI tract and provide timely diagnoses and treatment. We're excited to expand upon the innovations of our EVIS X1 endoscopy system with this combined imaging mode capability and continue elevating the standard of care."Physicians attending JDDW, scheduled for October 30–November 1, 2025 at the Kobe Convention Center will have the opportunity to see the combined NBI+TXI imaging mode firsthand.1 CANCER INCIDENCE OF JAPAN 2021About OlympusAt Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global LinkedIn and X accounts.Media contact:Mail: Global-Public_Relations@olympus.com.Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com    Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Boehringer Ingelheim mua lại giấy phép từ Kyowa Kirin nhằm phát triển phương pháp điều trị mới cho bệnh nhân mắc các bệnh tự miễn

Chương trình phân tử nhỏ được cấp phép nhằm giải quyết những nhu cầu chưa được đáp ứng đáng kể đối với các bệnh tự miễn.  Chương trình bổ sung vào danh mục sản phẩm của Boehringer Ingelheim và cam kết của họ nhằm mang lại các liệu pháp đột phá cho bệnh nhân mắc bệnh viêm.  (SeaPRwire) -   Ingelheim, Đức, và Tokyo, Nhật Bản, [Ngày 30 tháng 10, 2025] – Boehringer Ingelheim và Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, Chủ tịch kiêm COO: Abdul Mullick) hôm nay đã công bố rằng Boehringer Ingelheim đã cấp phép một chương trình tiền lâm sàng từ Kyowa Kirin để phát triển một phân tử nhỏ tiềm năng đầu tiên trong loại, nhằm điều trị các bệnh tự miễn.  Các bệnh tự miễn đại diện cho một thách thức sức khỏe toàn cầu đáng kể và ngày càng tăng, ảnh hưởng đến khoảng một trong mười người và gây gánh nặng đáng kể cho bệnh nhân và hệ thống chăm sóc sức khỏe. Mặc dù có những tiến bộ trong đổi mới liệu pháp, vẫn còn nhu cầu cao về các lựa chọn điều trị hiệu quả và lâu dài hơn. Là một nhà lãnh đạo được công nhận trong nghiên cứu và phát triển bệnh tự miễn, Boehringer Ingelheim thúc đẩy các phương pháp tiếp cận mới nhắm vào nguyên nhân gốc rễ của các tình trạng tự miễn, với mục tiêu cung cấp các liệu pháp mới có mục tiêu cao.  “Cam kết của chúng tôi trong việc cung cấp các liệu pháp thay đổi cuộc sống cho bệnh nhân mắc bệnh tự miễn là không lay chuyển. Chúng tôi rất vui mừng khi bổ sung một chương trình tiềm năng đầu tiên trong loại vào danh mục sản phẩm đang phát triển của chúng tôi,” Carine Boustany, Trưởng Đơn vị Đổi mới Hoa Kỳ và Trưởng Bộ phận Miễn dịch học và Bệnh Hô hấp Toàn cầu tại Boehringer Ingelheim cho biết. “Thỏa thuận này là một bước quan trọng hướng tới việc cung cấp các phương pháp điều trị đột phá cho bệnh nhân.”  Takeyoshi Yamashita, Tiến sĩ, Phó Chủ tịch Điều hành và Giám đốc Y tế của Kyowa Kirin, nhận xét, “Hợp chất này, được phát hiện thông qua chuyên môn sâu sắc của Kyowa Kirin về công nghệ đổi mới và sinh học bệnh lý, nắm giữ tiềm năng to lớn. Với việc tận dụng chuyên môn nổi tiếng của Boehringer Ingelheim trong các bệnh viêm nhiễm, chúng tôi tin tưởng rằng sự đổi mới này sẽ được phát triển hiệu quả và mang đến cho những bệnh nhân cần nhất.”   Theo các điều khoản của thỏa thuận, Boehringer Ingelheim sẽ nhận được các quyền độc quyền trên toàn thế giới từ Kyowa Kirin để phát triển chương trình phân tử nhỏ này. Kyowa Kirin đủ điều kiện nhận tới 640 triệu euro, bao gồm khoản thanh toán trả trước, các khoản thanh toán cột mốc phát triển, quy định và thương mại dựa trên thành công, ngoài tiền bản quyền trên doanh số bán hàng có thể có.  Boehringer Ingelheim  Boehringer Ingelheim là một công ty dược phẩm sinh học hoạt động trong cả lĩnh vực sức khỏe con người và động vật. Là một trong những nhà đầu tư hàng đầu của ngành vào nghiên cứu và phát triển, công ty tập trung vào việc phát triển các liệu pháp đổi mới có thể cải thiện và kéo dài cuộc sống ở những lĩnh vực có nhu cầu y tế cao chưa được đáp ứng. Độc lập kể từ khi thành lập vào năm 1885, Boehringer Ingelheim có tầm nhìn dài hạn, lồng ghép tính bền vững dọc theo toàn bộ chuỗi giá trị. Khoảng 54.500 nhân viên của chúng tôi phục vụ hơn 130 thị trường để xây dựng một tương lai khỏe mạnh hơn và bền vững hơn. Tìm hiểu thêm tại .    Kyowa Kirin  Kyowa Kirin đặt mục tiêu khám phá và cung cấp các loại thuốc và phương pháp điều trị mới có giá trị thay đổi cuộc sống. Là một Công ty Dược phẩm Chuyên khoa Toàn cầu có trụ sở tại Nhật Bản, Kyowa Kirin đã đầu tư vào đổi mới khám phá thuốc và công nghệ sinh học trong hơn 70 năm và hiện đang nỗ lực phát triển thế hệ kháng thể, liệu pháp tế bào và gen tiếp theo với tiềm năng giúp đỡ bệnh nhân có nhu cầu y tế cao chưa được đáp ứng, như bệnh xương & khoáng chất, các bệnh huyết học/huyết học ung thư khó chữa và các bệnh hiếm gặp. Một cam kết chung đối với các giá trị của Kyowa Kirin, tăng trưởng bền vững và làm cho mọi người mỉm cười đã đoàn kết Kyowa Kirin trên toàn cầu. Bạn có thể tìm hiểu thêm về hoạt động kinh doanh của Kyowa Kirin tại .   Thông báo về Đối tượng Dự kiến  Thông cáo báo chí này được phát hành từ Trụ sở chính của chúng tôi tại Ingelheim, Đức và nhằm cung cấp thông tin về hoạt động kinh doanh toàn cầu của chúng tôi. Xin lưu ý rằng thông tin liên quan đến tình trạng phê duyệt và nhãn sản phẩm đã được phê duyệt có thể khác nhau giữa các quốc gia, và một thông cáo báo chí cụ thể cho từng quốc gia về chủ đề này có thể đã được phát hành tại các quốc gia nơi chúng tôi hoạt động kinh doanh.  Liên hệ Truyền thông   Boehringer Ingelheim:    Dr. Reinhard Malin Boehringer Ingelheim Corporate Center GmbH  Đơn vị Đổi mới/Truyền thông Sinh học, Đối ngoại Doanh nghiệp  Truyền thông + PR      Kyowa  Kirin:  Nobuyuki Manita  Kyowa Kirin Co., Ltd. Truyền thông Doanh nghiệp  Truyền thông: media@kyowakirin.com  Nhà đầu tư: ir@kyowakirin.com  Tệp đính kèm Bài viết được cung cấp bởi nhà cung cấp nội dung bên thứ ba. SeaPRwire (https://www.seaprwire.com/) không đưa ra bảo đảm hoặc tuyên bố liên quan đến điều đó. Lĩnh vực: Tin nổi bật, Tin tức hàng ngày SeaPRwire cung cấp phát hành thông cáo báo chí thời gian thực cho các công ty và tổ chức, tiếp cận hơn 6.500 cửa hàng truyền thông, 86.000 biên tập viên và nhà báo, và 3,5 triệu máy tính để bàn chuyên nghiệp tại 90 quốc gia. SeaPRwire hỗ trợ phân phối thông cáo báo chí bằng tiếng Anh, tiếng Hàn, tiếng Nhật, tiếng Ả Rập, tiếng Trung Giản thể, tiếng Trung Truyền thống, tiếng Việt, tiếng Thái, tiếng Indonesia, tiếng Mã Lai, tiếng Đức, tiếng Nga, tiếng Pháp, tiếng Tây Ban Nha, tiếng Bồ Đào Nha và các ngôn ngữ khác. 

Northeast Asia Video Summit Spotlights Global Content Strategies, Streaming Innovation, and the Future of Media Monetization

TOKYO, Japan – October 30, 2025 - (ACN Newswire via SeaPRwire.com) - The Northeast Asia Video Summit 2025, hosted by the Asia Video Industry Association (AVIA), brought together leading media executives, content creators, and technology innovators to explore the future of video in Japan and Korea. Held in Tokyo, the summit showcased transformative strategies in global content production, streaming monetization, and cross-border collaboration.A central theme of the summit was the global ascent of Japanese and Korean content. In a compelling keynote, Katsuaki Setoguchi, Executive Officer at TBS Holdings and President and CEO of THE SEVEN Inc., emphasized that Japan’s ambition to go global is rooted not in profit, but in cultural promotion. “Storytelling is our foundation,” Setoguchi said, highlighting the success of Alice in Borderland and upcoming co-productions with U-Next. He outlined a formula for global success: strategic IP selection, elevated production budgets, and partnerships with platforms like Netflix and Amazon to reach a global audience. Setoguchi also stressed the importance of long-term regional collaboration, particularly in Southeast Asia, citing their strategic alliance with Vietnam TV.Yu Sasamoto, CEO of DAZN Japan and APAC Business Development, shared insights into Japan’s evolving sports streaming landscape. With partnerships like Docomo and Meta, DAZN is redefining how fans engage with live sports. Sasamoto revealed that DAZN is set to triple its subscriber base in Japan and is leveraging social media to convert engagement into subscriptions. Sasamoto also shared his ambitions to expand Japanese sports globally by building an ecosystem that blends content, technology, and partnerships to scale across Asia.Streaming monetization was another hot topic. Joshua Sunghyun Cho, CBO of TVING, detailed the platform’s innovative ad strategies, including impression-guaranteed products and interactive formats like “Watch Together.” Partnering with Moloco, TVING doubled its ad revenue from KBO baseball broadcasts and is now targeting contextual and shopping ads. “Streaming is no longer just premium branding—it’s performance-driven,” Cho said. Nick Chuah, Managing Director APAC at INVIDI, added that addressable advertising is poised to reshape Japan’s TV ad market, with data-driven campaigns delivering measurable ROI and unlocking new value for brands.Executives from Dentsu, FAST Corporation, and Integral Ad Science also echoed the need for collaboration, standardization, and advocacy to accelerate CTV adoption in Japan. With new smart TVs and platforms like TVer and ABEMA entering the programmatic space, the market is poised for rapid growth.The summit also addressed the future of anime as a global cultural force. Yuichiro Saito, CEO of Studio CHIZU, and Hideki Henry Goto, President of OKUTAGON LLC, discussed anime’s expanding international footprint. With over half of revenue now coming from global markets, speakers called for new business models, international co-productions, and talent development to sustain growth, with Saito advocating for creative integrity and global collaboration.In the closing keynote, executives from Warner Bros. Discovery, SKY Perfect JSAT, and A+E Global Media debated the future of pay TV and streaming economics in Japan. While acknowledging the slow decline of linear TV, they emphasized the enduring value of local partnerships and bundling strategies. Japan’s rich history and vibrant culture continue to produce compelling stories, presenting vast opportunities for international partnerships to bring this content to global audiences. The speakers agreed that creative distribution models and co-productions will be key to unlocking Japan’s full potential on the global stage.The Northeast Asia Video Summit is proudly sponsored by Gold Sponsors Moloco and Publica by IAS, and Silver Sponsors Encompass, INVIDI and TV5MONDE.Click here for a selection of photos from the Summit.About the Asia Video Industry AssociationThe Asia Video Industry Association (AVIA) is the trade association for the video industry and ecosystem in Asia Pacific. It serves to make the video industry stronger and healthier through promoting the common interests of its members. AVIA is the interlocutor for the industry with governments across the region, leads the fight against video piracy through its Coalition Against Piracy (CAP) and provides insight into the video industry through reports and conferences aimed to support a vibrant video industry.For media enquiries and additional background information, please contact:Charmaine KwanHead of Marketing and CommunicationsEmail: charmaine@avia.org | Website: www.avia.orgLinkedIn: www.linkedin.com/company/asiavideoia |X: @AsiaVideoIA  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

TOKYO and RAHWAY, NJ, Oct. 29, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai (Headquarters: Tokyo, CEO: Haruo Naito) and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced results from that Phase 3 LEAP-012 trial evaluating LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI)discovered by Eisai, plus KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co.,Inc., Rahway, NJ, USA, in combination with transarterial chemoembolization (TACE) for the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC).At a pre-specified interim analysis, LENVIMA plus KEYTRUDA in combination with TACE did not achieve statistical significance for overall survival (OS), one of the study’s primary endpoints, compared to TACE alone. The likelihood of reaching the protocol-specified threshold for statistical significance for OS at a future analysis was evaluated by Eisai and Merck & Co.,Inc., Rahway, NJ, USA and considered to be low. On this basis, the study will be closed, and the companies are informing investigators of this decision.The safety profile of the LENVIMA plus KEYTRUDA-based regimen was consistent with that observed in previously reported studies evaluating the combination and in earlier analyses of LEAP-012. Further analysis of the data is ongoing. Eisai and Merck & Co., Inc., Rahway, NJ, USA will work with investigators to share the results with the scientific community.As reported previously, LENVIMA plus KEYTRUDA in combination with TACE met the study’s other primary endpoint of progression-free survival (PFS) and demonstrated a statistically significant and clinically meaningful improvement compared to TACE alone. Data from this first interim analysis, which served as the final analysis for the endpoint of PFS, were presented at the European Society for Medical Oncology (ESMO) Congress 2024 and published in The Lancet. With additional follow-up at subsequent analyses, PFS remained consistent.“Although the progression-free survival results from this study are encouraging, unfortunately, the addition of KEYTRUDA plus LENVIMA to TACE did not show the overall survival benefit we hoped,” said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, MSD Research Laboratories. “We are grateful to the patients and investigators for their important contributions to this study, and our commitment is unwavering as we pursue new therapeutic options for people living with hepatocellular carcinoma, an aggressive and challenging-to-treat cancer.”“The overall survival findings from LEAP-012, along with the previously reported improvement in progression-free survival, provide important insights for treating unresectable, non-metastatic hepatocellular carcinoma,” said Dr. Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai. “For years, TACE has been a standard of care for these patients, yet many experience disease progression within twelve months. With LEAP-012, we sought to make a meaningful difference for this patient population. LENVIMA continues to play an important role as a monotherapy treatment option for patients with unresectable HCC, and as a company with a deep heritage in liver cancer research, Eisai remains committed to advancing the science.”In July 2025, LENVIMA plus KEYTRUDA in combination with TACE was approved in China to treat unresectable non-metastatic HCC. The LENVIMA plus KEYTRUDA combination is approved in the U.S., the European Union (EU), Japan and other countries for the treatment of advanced renal cell carcinoma (RCC) and certain types of advanced endometrial carcinoma. Results from the LEAP-012 trial do not affect the current approved indications for the LENVIMA plus KEYTRUDA combination, including the approval of LENVIMA plus KEYTRUDA in combination with TACE in China to treat unresectable non-metastatic HCC.LENVIMA monotherapy is approved for the treatment of patients with unresectable HCC in more than 80 countries and regions, including in the U.S., the EU, China and Japan.KEYTRUDA is approved as a monotherapy for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen in the U.S. and as a monotherapy for the treatment of patients with HCC who have been previously treated with sorafenib or oxaliplatin-containing chemotherapy in China.For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202576pdf.pdf  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Mazda Presents World Premiere of Two Vision Models at Japan Mobility Show 2025

HIROSHIMA, Japan, October 29, 2025 - (JCN Newswire via SeaPRwire.com) - During the press conference at the Japan Mobility Show 2025(*1) today, Mazda Motor Corporation (Mazda) unveiled two vision models, the MAZDA VISION X-COUPE and the MAZDA VISION X-COMPACT (‘X’ pronounced as ‘cross’ ), both embodying the Company’s theme for this year's exhibition: “The Joy of Driving Fuels a Sustainable Tomorrow” for 2035.The MAZDA VISION X-COUPE is a crossover coupe that embodies the further evolution of ‘KODO-Soul of Motion’ design language. It is powered by a plug-in hybrid system integrating a two-rotor rotary turbo engine with a motor and battery. With a maximum output of 510 PS, the vehicle offers a driving range of 160 km in motor-only mode and up to 800 km when operating in combination with the engine. Furthermore, by combining carbon-neutral fuel derived from microalgae with Mazda’s proprietary CO2 capture technology, “Mazda Mobile Carbon Capture,” the vehicle contributes to reducing atmospheric CO2 the more it is driven.MAZDA VISION X-COUPEThe MAZDA VISION X-COMPACT is a model designed to deepen the bond between people and cars through the fusion of a human sensory digital model and empathetic AI. Acting like a close companion, it is capable of engaging in natural conversation and suggesting destinations, helping expand the driver’s world. This represents Mazda’s vision for the future of smart mobility, where vehicles and people form an emotional connection, much like a friend.MAZDA VISION X-COMPACTFurthermore, the All-New MAZDA CX-5 (European specification) (*2) , is on display to the general public for the first time ever. Featuring a spacious interior, refined KODO design, and enhanced Jinba-ittai (oneness between driver and car) driving dynamics, this model represents the evolution of a best-selling vehicle that has sold over 4.5 million units (*3) across more than 100 countries and regions. Designed with the new electronic platform “MAZDA E/E ARCHITECTURE+”, this latest model aims to offer an evolved driving experience.Masahiro Moro, Representative Director, President and CEO of Mazda, stated: “The phrase, ‘The joy of driving fuels a sustainable tomorrow,’ expresses not only Mazda’s fundamental spirit, but also the core of its future challenges. Under the shared global mission of achieving carbon neutrality, Mazda believes that the joy of driving can be a force for positive change for society and the planet. We remain committed to fulfilling the desire of those who love cars and wish to continue driving forever.”Mazda will continue to evolve the ‘Joy of Driving’ based on the value of ‘Radically Human,’ and will aim to deliver the ‘Joy of Living’ by creating exciting mobility experiences in our customers' daily lives.Overview of the MAZDA VISION X-COUPE and MAZDA VISION X-COMPACTModelMAZDA VISION X-COUPEMAZDA VISION X-COMPACTOverall Length5,050 mm3,825 mmOverall Width1,995 mm1,795 mmOverall Height1,480 mm1,470 mmWheelbase3,080 mm2,515 mm*1 Hosted by the Japan Automobile Manufacturers Association, Inc.Press Day: Wednesday, October 29, 8:00-18:00, and Thursday, October 30, 8:00-13:00.Public Day: starting Friday, October 31 until Sunday, November 9.*2 For the new MAZDA CX-5, please see the news release at the following URL.https://newsroom.mazda.com/en/publicity/release/2025/202507/250710a.html*3 Mazda's best-selling model in its current lineup from 2018 to 2024  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025

HIROSHIMA, Japan, October 29, 2025 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation (Mazda) announced today that it will gradually roll out a new version of its brand symbol, embodying its unwavering belief and enduring commitment to shaping the future. This brand symbol will also be featured at the Mazda booth at the Japan Mobility Show 2025, a place to showcase the future of the Mazda brand to the world, delivering Mazda's new brand expression to visitors.  Mazda booth at Japan Mobility Show 2025 featuring the new version of the brand symbolThe new version of Mazda’s brand symbol inherits the spirit of its symbol introduced in June 1997, representing the letter 'M' with the evocation of soaring wings. This embodies the Company’s commitment to continuous self-reform and dynamic, unceasing growth. It demonstrates the evolution of the brand toward the next generation.The sleek and bold form enhances visibility, particularly in digital environments, resulting in a more refined design. The new version of the wordmark, launched alongside it, adopts a modern style. The new version of the brand symbol and wordmark are now being adopted on the Mazda corporate website starting today.New version of the brand symbol in the digital areaThe new version of the brand symbol and the current brand symbol will be applied optimally according to location and media characteristics to enhance global brand recognition.Mazda will continue to pursue the "Joy of Driving" under its core value of “Radically Human,” and aim to deliver the "Joy of Living" by creating moving mobility experiences in the daily lives of its customers.*Definition of Each Mark Reference- Mazda corporate website featuring the new version of the brand mark:https://www.mazda.com/en/- Mazda brand mark history page:https://www.mazda.com/en/about/history/mark- Japan Mobility Show 2025 Mazda Exhibit Release:https://newsroom.mazda.com/en/publicity/release/2025/202510/251014a.html  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI

TOKYO, Japan, October 29, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) and the Cambodian Mine Action Center (CMAC, *1), the national institution responsible for landmine clearance activities in Cambodia, with assistance from JICA (*2), conducted a proof-of-concept using AI to predict landmine-contaminated areas. This initiative aims to contribute to rapid and efficient clearance operations to eliminate landmine casualties. The proof-of-concept achieved highly accurate predictions, with a match rate exceeding 90% against actual landmine locations.This initiative also received recognition through "The GICHD Innovation Award 2025," hosted by the Geneva International Centre for Humanitarian Demining (GICHD, *3), which honors outstanding technologies contributing to progress in demining activities. The award was presented at a ceremony held in Luxembourg on Tuesday, October 28. Removing landmines in an area                                   Award Ceremonypredicted by AI in Cambodia                                     ©GICHD/PANCAKE! PhotographieThe use of landmines remains a humanitarian issue worldwide, particularly hindering community and economic development for extended periods in post-conflict nations. It is estimated that approximately 100 million people face the threat of landmines, with one person losing their life to a landmine every 90 minutes (*4).In Cambodia, civil war spanning the 1970s and 1990s led to the widespread burial of landmines across the country. Despite years of dedicated clearance efforts, remnant landmines persist in some areas today. These landmines prevent the use of land for farming and residential purposes, posing serious obstacles to recovery and development.The Cambodian government, based on the Ottawa Treaty (Convention on the Prohibition of the Use, Stockpiling, Production and Transfer of Anti-Personnel Mines and on Their Destruction) signed in 1997, has set a target of completing landmine clearance within Cambodia by 2030. To achieve this, it is expected that advanced technologies such as AI will be utilized to reduce survey time.This demonstration targeted approximately 1 million square meters of Cambodia's landmine fields. NEC's AI analyzed information based on data that included CMAC's records of detected landmine locations, resident-provided information, and open data such as river/mountainous terrain locations and factory/critical building sites. It then accurately predicted areas with a high probability of containing buried landmines.Traditionally, identifying potential landmine-infested areas required extensive, unorganized data and significant manpower over long periods. By leveraging AI, this process can now be performed quickly with fewer personnel, demonstrating the potential to support swift and efficient landmine clearance.Going forward, NEC will continue striving to further improve AI's accuracy. Working with CMAC, with assistance from JICA, and strengthening collaboration with the Japanese government, NEC will accelerate efforts toward achieving Cambodia's goal of completing landmine clearance by 2030. Furthermore, NEC aims to contribute to other landmine-affected countries using this technology in the future.(*1) Cambodian Mine Action Center (CMAC)Location: Phnom Penh, Cambodia; Director: Heng Rathana(*2) Japan International Cooperation Agency(*3) Geneva International Center for Humanitarian Demining (GICHD)Location: Geneva, Switzerland; Director: Stefano Toscan(*4) Source: the-monitor.org/reports/landmine-monitorLandmine Monitor 2024 Full PaperAbout NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Overview of Honda CEO Speech at the Japan Mobility Show 2025

TOKYO, Japan, October 29, 2025 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. Director, President and Representative, Toshihiro Mibe today held a press conference at the Japan Mobility Show 2025.Following is an overview of his remarks, including support information:Honda exhibits mobility products and technologies for land, sea, skies and outer spaceWorld premiere of prototype of Honda 0 α, new SUV model for the Honda 0 SeriesWorld premiere of EV OUTLIER Concept, new vision for motorcycles beyond 2030World premiere of Super-ONE Prototype, compact EV will create excitement and uplifting feeling in people’s daily livesHonda exhibits sustainable rocket used for launch and landing test in June 2025About Japan Mobility Show 2025Honda is a company that has always put its heart and soul into realizing its own dreams. This year, Honda is exhibiting a wide variety of mobility products and technologies for land, sea and skies, and also for outer space. Honda would like visitors to ride and touch these items on display to feel the excitement for the future envisioned by Honda. Next-generation EVs for electrified eraHonda is working toward an ambitious goal of achieving carbon neutrality for all of its products and corporate activities by 2050. Although the market environment surrounding electrification continues to be uncertain, Honda believes that, in the long run, the shift toward EVs will continue. Therefore, Honda is steadily preparing to deliver attractive EV models in the upcoming electrified era.Honda 0 Series, next-generation EVs of Honda Honda 0 Series is the next-generation series of EVs that Honda will offer by going back to the starting point of Honda as an automaker and creating new EVs from “zero” based on original ideas. With the unique development approach of “Thin, Light, and Wise.”, Honda 0 Series will defy existing conventions that EVs are “thick and heavy” and create completely new value.   The prototype of the Honda 0 Saloon, the flagship model of Honda 0 Series, is built on a low-floor platform dedicated to EVs and features both sporty styling with a low vehicle height and a much more spacious cabin space than people would expect from the exterior design.The prototype of the Honda 0 SUV, a mid-size SUV which is the first Honda 0 Series model scheduled for market launch, features a spacious cabin with a clear and unrestricted field of view and great flexibility, realized by applying the unique “Thin, Light, and Wise.” development approach to an SUV to further increase the interior space.  Honda 0 Saloon Prototype                                 Honda 0 SUV PrototypeThese models feature ASIMO OS, the original Honda vehicle OS, which will enable continuous advancement of various functions even after the purchase of the vehicle. So, the more the customer uses it, the more personalized the car becomes to offer “ultra-personal optimization” of the customer’s mobility experience.  Honda 0 α, a new SUV for Honda 0 SeriesHonda is presenting the world premiere of the prototype of the Honda 0 α (alpha), a new SUV model for the Honda 0 Series. Featuring a sleek and sophisticated design unique to Honda 0 Series and original proportions that express the dynamic nature of SUVs, the Honda 0 α will blend beautifully with both urban and natural environments, supporting people’s lives in every situation.By applying packaging design based on the “Thin” approach, styling with a low vehicle height was achieved without compromising ground clearance, creating a thin cabin that still offers a spacious and comfortable space for occupants.Honda is planning to begin global sales of the production model of Honda 0 α, mainly in Japan and India, in 2027. With this “gateway model” to the Honda 0 Series, Honda will strive to offer new value to a greater number of customers around the world. In Japan, three Honda 0 Series models — Honda 0 Saloon, Honda 0 SUV, and Honda 0 α — will go on sale before the end of the fiscal year ending March 31, 2028. Honda 0 α PrototypeAcura RSX Prototype, a next-generation EV model for Acura brandHonda is also presenting the Japan premiere of the Acura RSX Prototype, a next-generation EV model for the Acura brand.The Acura RSX Prototype is the first model to adopt the next-generation EV platform developed independently by Honda. It also features ASIMO OS, the original Honda vehicle OS, which will enable the vehicle to learn the preferences and driving patterns of each customer and realize “ultra-personal optimization” of the mobility experience.Acura RSX Prototype *The model on display will feature a different color.EV OUTLIER Concept, a new electric motorcycle model that proposes a new vision for motorcycles beyond 2030Honda is presenting the world premiere of the EV OUTLIER Concept. Not just an extension of existing motorcycles, this concept model proposes a new vision for motorcycles beyond 2030.Taking advantage of the high degree of freedom of the layout unique to electric motorcycles, the EV OUTLIER Concept features in-wheel motors on both the front and rear wheels, achieving dynamic and low-proportion styling. Through electrification, Honda will continue to create unprecedented value with its motorcycles as well. EV OUTLIER ConceptThe “joy of driving,” the enduring philosophy of HondaWhile preparing for the upcoming electrified era, the pursuit of the “joy of driving” unique to Honda – the sense of oneness the driver feels with the vehicle – will never change regardless of the times or type of powertrain. Honda is offering a wide range of products that enable its customers to experience this “joy of driving,” whether they are EV or hybrid models.Super-ONE Prototype, a compact EV that creates excitement and an uplifting feeling in people’s daily livesHonda is presenting the world premiere of the Super-ONE Prototype, a compact EV filled with the playful mind of Honda, which will create new excitement and an uplifting feeling in people’s daily lives.Leveraging the lightweight platform advanced for N Series models, the Super-ONE Prototype realizes sporty and nimble driving. In addition, its wide stance with extended tread, realized by prominently flared blister fenders, enables a stable and dynamic driving experience.Moreover, it features “Boost Mode” developed exclusively for this model. As the power output increases, engine sound fills the cabin in sync with the feeling of shifting gears, as if driving an engine-powered vehicle. The Super-ONE offers an uplifting driving experience by combining outstanding acceleration unique to EVs and the fun of driving engine-powered vehicles.Starting in 2026, the Super-ONE will be launched first in Japan, followed by other markets with strong demand for compact EVs, such as various Asian countries and the U.K. Super-ONE PrototypePrelude, a specialty sports model embodying the unrelenting Honda sports mindsetHonda is also exhibiting the new Prelude, a specialty sports model Honda developed by fully applying an engine and technologies that Honda has perfected over many years, to carry forward the “joy of driving” into the full-fledged electrified era. The development of the new Prelude began with a strong desire to create a model that represents the Honda of today, and it was perfected as a model Honda recommends with absolute confidence.New PreludeCreating new value through enhanced application of intelligent technologiesHonda is striving to continue offering new value through a variety of mobility products and services. The key element in realizing such new value is the enhanced application of intelligent technologies. As one of the core intelligent technologies, Honda is strengthening the development of its next-generation ADAS.When the driver sets a destination on the navigation system, the ADAS will enable the vehicle to take charge of driving, such as controlling the accelerator and steering wheel, to achieve a comfortable ride to the destination. This function will give the driver peace of mind as if an experienced driver is in charge of driving operations, which will provide confidence even on unfamiliar roads and significantly reduce the burden of driving.Honda is currently testing its next-generation ADAS on public roads in the U.S., making steady progress in development. Starting around 2027, Honda will apply this technology not only to its EVs, but also to hybrid models to offer new value to the greater number of customers through their experience of expanding the freedom of mobility.  A wide variety of mobility products and technologies for land, sea, skies and outer spaceIn addition to motorcycle and automobile products and technologies, as a comprehensive mobility company, Honda has been offering a wide range of mobility products for land, sea, and skies. Including power products such as tillers and outboard motors, as well as the HondaJet, a light business jet, Honda is offering a wide variety of mobility products that will help people expand their life’s potential.Including next-generation mobility products such as micromobility vehicles that will make last-mile mobility more convenient, and eVTOLs that will make mobility in the skies more accessible for more people, Honda will continue taking on challenges to spread the “joy and freedom of mobility” to more people.And now, Honda has expanded its challenges to outer space.Outer space - Taking on a new frontier with sustainable rocketsThe actual rocket Honda used for the launch and landing test conducted in Hokkaido, Japan in June 2025 is also on display at the Honda booth. Honda is striving to develop environmentally-responsible “sustainable rockets” which will enable the reuse of the rocket as well as the use of renewable fuel.  Test being conducted in Hokkaido, Japan          Actual launch and landing test in June 2025(Photo taken in May, 2025)In the testing in June, precise control was applied on the rocket’s attitude and speed from takeoff to landing, to achieve the exact rocket behaviors planned. This success was achieved by the collective strength of Honda technologies, including control technologies amassed through automated driving and aircraft development, as well as the passion of each and every Honda associate “at the spot” who kept taking on challenges with determination.Honda rocket research and development has just taken its first step. No matter what difficulties lie ahead, Honda will overcome them by continuing to take on challenges without giving up. ClosingIn line with the Honda Global Brand Slogan — The Power of Dreams — How we move you. — each and every Honda associate with dreams and passion will continue taking on new challenges to carve out the future of Honda and create value only Honda can create.The Honda booth is introducing the future Honda aims to realize through its wide variety of mobility products and technologies, enabling visitors to feel excitement for the future. For more details, please visit: https://global.honda/en/newsroom/news/2025/c251029eng.html  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com